NASDAQ:SGRY
Surgery Partners, Inc. (NASDAQ: SGRY) Faces Challenges but Shows Potential for Recovery
Font: Financial Modeling Prep • Mar 03, 2026
- Surgery Partners, Inc. (NASDAQ: SGRY) missed Q4 earnings expectations but reported a 2.4% increase in sales year over year.
- The company’s stock hit a 52-week low following disappointing fourth-quarter results and a cautious outlook for 2026.
- Despite challenges, the consensus analyst price target stands at approximately $26.67, suggesting substantial potential upside from current levels.
Surgery Partners, Inc. (NASDAQ: SGRY) is a healthcare services company that operates surgical facilities across the United States. The company provides a range of surgical services, including orthopedics, pain management, and ophthalmology. SGRY competes with other healthcare service providers like Tenet Healthcare and HCA Healthcare.
On March 3, 2026, amid the post-earnings reaction, the stock traded around $13.41 during the session. Despite the market reaction, SGRY’s stock price recently hit a 52-week low during a premarket session. This decline followed the release of disappointing fourth-quarter results and a cautious outlook for 2026. The company reported adjusted earnings of 12 cents per share, missing the expected 30 cents. This shortfall contributed to the stock’s decrease of approximately 12.91%, with a change of $2.05, bringing the price to $13.83 at one point during the session. However, not all news was negative for SGRY.
The company reported a 2.4% increase in sales year over year, reaching $885 million, which surpassed the consensus estimate of $866.47 million. Same-facility revenues for the fourth quarter of 2025 also saw a 3.5% increase, with revenue per case rising by 2.1% and same-facility cases increasing by 1.3%. These figures indicate some positive operational performance despite the overall challenges. The adjusted EBITDA for the fourth quarter was $156.9 million, down from $163.8 million the previous year. Additionally, cash flows from operating activities decreased to $103.4 million, compared to $111.4 million in the fourth quarter of 2024.
CEO Eric Evans acknowledged significant and unanticipated headwinds faced by the company, which contributed to the cautious outlook for 2026. SGRY’s market capitalization is approximately $1.79 billion, with a trading volume of 4,007,837 shares. The stock has fluctuated between a low of $12.25 and a high of $13.83 today, with a 52-week high of $24.64. Despite recent setbacks, the consensus analyst price target suggests potential for recovery and growth in the future.
Market Overview
|
BHAT
Fujian Blue Hat Interactive Entertainment Technology Ltd.
|
$0.04
27.18%
|
|
TPET
Trio Petroleum Corp.
|
$1.59
87.28%
|
|
MOBX
Mobix Labs, Inc.
|
$0.87
5.61%
|
|
QNCX
Quince Therapeutics, Inc.
|
$0.11
5.19%
|
|
GXAI
Gaxos.ai Inc.
|
$1.81
45.97%
|
|
IBO
Impact BioMedical Inc.
|
$0.64
55.46%
|
|
TZA
Direxion Daily Small Cap Bear 3X ETF
|
$6.54
5.65%
|
|
NVDA
NVIDIA Corporation
|
$183.34
0.16%
|
|
UOKA
MDJM Ltd
|
$0.08
9.92%
|
|
TQQQ
ProShares - UltraPro QQQ
|
$49.80
-0.92%
|
